louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05277259: Comparative Effects of Conventional Physical Therapy, Kinesio Taping and ESWT in Upper Trapezius MPS.
Official title: Comparative Effects of Conventional Physical Therapy, Kinesio Taping and Extracorporeal Shock Wave Therapies in Upper Trapezius Myofascial Pain Syndrome.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Trapezius Muscle Strain
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2022-03-14
Enrollment: 99
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There is no study in the literature comparing both kinesiotaping and Extracorporeal Shock Wave Therapy (ESWT) with conventional physical therapy in upper trapezius myofascial pain syndrome. In this study, we aimed to make this comparison.


Eligibility criteria: Inclusion Criteria:

* Presence of at least 1 active trigger point in the upper trapezius muscle, exacerbation of pain when this point(s) is pressed, painful limitation of cervical lateral flexion and extension.

Exclusion Criteria:

* Having a history of spine and upper extremity surgery, neuromuscular disease, active rheumatologic disease, active infection, malignancy, having previously applied ESWT or Kinesio Taping to the back and neck region.

Primary outcomes:
measure: Visual Analogue Scale (VAS)
timeFrame: at baseline (before the treatment)
measure: Visual Analogue Scale (VAS)
timeFrame: 2 weeks after baseline (at the end of treatment)
measure: Visual Analogue Scale (VAS)
timeFrame: 6 weeks after baseline (one month after the end of treatment)
measure: Neck Disability Index (NDI)
timeFrame: at baseline (before the treatment)
measure: Neck Disability Index (NDI)
timeFrame: 2 weeks after baseline (at the end of treatment)
measure: Neck Disability Index (NDI)
timeFrame: 6 weeks after baseline (one month after the end of treatment)
Secondary outcomes:
measure: Measurement of Cervical range of motion (Cervikal ROM)
timeFrame: at baseline (before the treatment)
measure: Measurement of Cervical range of motion (Cervikal ROM)
timeFrame: 2 weeks after baseline (at the end of treatment).
measure: Measurement of Cervical range of motion (Cervikal ROM)
timeFrame: 6 weeks after baseline (one month after the end of treatment)
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Yuzuncu Yil University
Study officials:
affiliation: Yüzüncü Yıl Üniversitesi Tıp Fakültesi
name: Volkan Şah
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04437459: The Reproducibility and Clinical Utility of an Abbreviated Fat Tolerance Test
Official title: The Reproducibility and Clinical Utility of an Abbreviated Fat Tolerance Test
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dyslipidemias
Metabolic Syndrome
Lead sponsor: Oklahoma State University
Sponsor class: OTHER
First posted: 2020-06-18
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SCREENING

Brief summary: This study aims to evaluate the reliability of a shortened fat tolerance test ("abbreviated fat tolerance test", or "AFTT") for measuring post-meal lipids in human blood. The reliability of the triglyceride results in this test are compared to the reliability of the glucose results from an oral glucose tolerance test (OGTT), a widely-used and clinically accepted metabolic test.


Eligibility criteria: Inclusion Criteria:

* Free of chronic disease
* Normal (healthy) fasting glucose and triglycerides

Exclusion Criteria:

* Presence of pace-maker
* Pregnant
* Using tobacco products
* Using medications or dietary supplements that could modify primary outcomes

Primary outcomes:
measure: Reliability of the Change in Triglycerides after a High-Fat Meal
timeFrame: The two fat tolerance tests are separated by 1 week.
measure: Reliability of the Change in Glucose after Ingestion of a Glucose Solution
timeFrame: The two glucose tolerance tests are separated by 1 week.
Secondary outcomes:
Other outcomes:
Locations:
city: Stillwater
country: United States
facility: Oklahoma State University
state: Oklahoma
Study officials:
affiliation: Oklahoma State University
name: Sam R Emerson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04555200: Continuous Enteral Rehydration by Nasogastric Tube With ORS in Children With Acute Gastroenteritis
Official title: Continuous Enteral Rehydration by Nasogastric Tube With ORS in Children With Acute Gastroenteritis: Evaluation of Professional Practices Before and After Protocol Change
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Gastroenteritis
Dehydration
Keywords: nasogastric tube
Emergency medicine
Pediatric medicine
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2020-09-18
Enrollment: 88
Sex: ALL
Minimum age (years): 1
Maximum age (years): 15
Standard ages: CHILD
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any child from 0 to 15 years presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included

Brief summary: When oral rehydration is impossible, enteral rehydration via the nasogastric route has been the recommended method of rehydration since 2008 by ESPGHAN ( European Society for Paediatric Gastroenterology Hepatology and Nutrition ), for children with acute gastroenteritis. However, these recommendations are rarely followed in France. These recommendations were not applied in the Children's Emergency Department of BREST University Hospital. The investigators changed the protocol and shared it with the caregivers of the emergency unit. The investigators studied the impact of this change of protocol

Detailed description: The main purpose was to assess the proportion of children rehydrated by nasogastric tube(NG) after protocol change. Secondary outcomes were to assess hospital length of stay and sides effects.

It is a retro and prospective study. The first phase took place from June to September 2018 and the second from June to September 2019. Any child presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included.

Eligibility criteria: Inclusion Criteria:

Any child presenting to pediatric emergencies for acute gastroenteritis requiring nonoral rehydration was included

Exclusion Criteria:

* acute gastroenteritis on return from tropical countries
* child with endocrine system diseases requiring parenteral rehydration
* history of chronic pathology requiring enteral feeding

Primary outcomes:
measure: Number of nasogastric tube after changing gastroenteritis rehydration protocol
timeFrame: 4 months
Secondary outcomes:
measure: Hospital lenght of stay between each group
timeFrame: 4 months
measure: Number of Participants With Treatment-Related Adverse Events for each method
timeFrame: 4 months
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest (urgences pédiatriques)
Study officials:
affiliation: CHRU Brest
name: Nadege Delaperriere, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02481700: Epidemiological Study on the Surgical Removal of Third Molars
Official title: Epidemiological Study on the Surgical Removal of Third Molars
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Impacted Third Molar Tooth
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2015-06-25
Enrollment: 6010
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All included patients are referred from primary dental providers for the surgical removal of one or more third molars

Brief summary: The aim of this study is to get a clear view on current practice of surgical third molar removal in Belgium and the association with morbidity and complications.

For this prospective cohort study, patients who visit the outpatient department of Oral and Maxillofacial Surgery of the University Hospitals Leuven or hospitals affiliated with the Flemish Hospital Network will be participating. All included patients are referred from primary dental providers for the surgical removal of one or more third molars. Before participating, written informed consent will be recorded from all eligible subjects.

Patients consult one of the oral and maxillofacial surgeons or residents working on the department of the University Hospitals Leuven for the removal of third molars. In the standard procedure, patients are not routinely clinically monitored after one week at the department.

Pre-operative, operative and postoperative data will be collected through a questionnaire, extracted data from the patient's medical file and panoramic radiography. The surgeon's individual operation technique will be registered through a one-off questionnaire. The questionnaires are taken at the same time of consultation and includes a maximum of 8 questions per time and are considered as non-invasive and a minimal burden for the patient. Postoperatively, patients record their recovery status and ability to resume daily- and work activities at day 3 and 10 by using a dairy system and, if necessary, revisit the outpatient department of oral and maxillofacial surgery.


Eligibility criteria: Inclusion Criteria:

* referred for the removal of one or more third molars

Exclusion Criteria:

* other concomitant oral procedures in the same surgical session

Primary outcomes:
measure: Morbidity
timeFrame: 10 days
Secondary outcomes:
measure: Resuming daily activities
timeFrame: 10 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02277600: A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)
Official title: Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Infection, Human Immunodeficiency Virus
Lead sponsor: ViiV Healthcare
Sponsor class: INDUSTRY
Collaborators: name: GlaxoSmithKline
First posted: 2014-10-29
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open-label, single sequence, 2-cohort, drug-drug interaction study in healthy male and female subjects. There is no formal hypothesis, however, it is expected that the coadministration of BMS-663068 with darunavir (DRV)/cobicistat (COBI) or COBI will increase the systemic exposure of BMS-626529.


Eligibility criteria: Inclusion Criteria:

* Healthy male and female
* Nonsmoking subjects
* Ages 18 to 50 years
* Inclusive with a body mass index of 18.0 to 32.0 kg/m2, inclusive
* Women of childbearing potential
* Must agree to follow instructions for methods of contraception for the duration of the study plus 34 days post-treatment completion

Exclusion Criteria:

* Any history of acute or chronic medical and surgical illness.
* Personal of family history of hemophilia A or B
* Other protocol defined exclusion criteria could apply

Primary outcomes:
measure: Pharmacokinetic parameters (maximum observed plasma concentration and area under the concentration-time curve in 1 dosing interval) for BMS-626529
timeFrame: predose and up to 12 hours post dose on Days 4 and 14
Secondary outcomes:
Other outcomes:
measure: Safety as assessed by adverse events and other physical parameters
timeFrame: From dosing (Day 1) to Day 14
Locations:
city: San Antonio
country: United States
facility: GSK Investigational Site
state: Texas
Study officials:
affiliation: ViiV Healthcare
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Moore K, Thakkar N, Magee M, Sevinsky H, Vakkalagadda B, Lubin S, Llamoso C, Ackerman P. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0225121. doi: 10.1128/aac.02251-21. Epub 2022 Mar 22.
Clinical trial NCT04821700: Atrial Fibrillation and Carotid Atherosclerosis in Ischemic Stroke Patients-(AFCAS)
Official title: Carotid Artery Atherosclerosis in Ischemic Stroke Patients With Atrial Fibrillation.(Atrial Fibrillation and Carotid Atherosclerosis in Ischemic Stroke Patients- AFCAS)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ischemic Stroke
Atrial Fibrillation
Carotid Stenosis
Keywords: Ischemic Stroke
Atrial fibrillation
carotid stenosis
atherosclerosis
Lead sponsor: University of Thessaly
Sponsor class: OTHER
First posted: 2021-03-29
Enrollment: 3000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Ischemic Stroke patients with atrial fibrillation

Brief summary: The main aim of the study is to investigate the prevalence and characteristics of ischemic stroke patients with atrial fibrillation and concurrent carotid atherosclerosis. Additionally, this study will investigate the effect of concurrent carotid atherosclerosis on the outcomes of recurrent stroke, myocardial infarction and death during follow-up


Eligibility criteria: Inclusion Criteria:

* Hospitalization due to ischemic stroke
* Atrial fibrillation
* Αny type of carotid vascular imaging

Exclusion Criteria:

* Intracerebral haemorrhage on admission
* Haemorrhagic transformation on admission

Primary outcomes:
measure: Stroke recurrence
timeFrame: From date of randomization until the date of stroke recurrence, assessed up to 60 months
measure: Myocardial infarction
timeFrame: From date of randomization until the date of myocardial infarction, assessed up to 60 months
measure: Death during follow-up
timeFrame: From date of randomization until the date of death from any cause, assessed up to 60 months
Secondary outcomes:
measure: modified Rankin Scale at 3 months
timeFrame: 3 months
Other outcomes:
Locations:
city: Larissa
country: Greece
facility: Medical School, University of Thessaly, Larissa University Hospital
Study officials:
References:
Clinical trial NCT06221800: Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Official title: A Pilot Study to Assess the Diversity of Gut Microbiome in Metastatic Non-Small Cell Lung Cancer (NSCLC) in Correlation to Treatment Effects and Adverse Effects
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Non Small Cell Lung Cancer
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2024-01-24
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient with advanced/metastatic non-small cell lung cancer (NSCLC)

Brief summary: This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.


Eligibility criteria: Inclusion Criteria:

* 1. Advanced/Metastatic non-small cell lung cancer NSCLC patients.
* 2. The patient himself/herself must be 18 years of age on day of signing informed consent.
* 3. The subject has signed the informed consent form.
* 4. The patient must be eligible to receive FDA approved and non-approved PD1 inhibitors (i.e. pembrolizumab, nivolumab) or PDL1 inhibitor (i.e. atezolizumab, durvalumab) either single agent or as combination therapy with chemotherapy, or be eligible to receive FDA approved and non-approved tyrosine kinase inhibitors.
* 5. The subject will be registered upon submission of the samples. When submitted on separate dates, the submission occurring later will be considered the date of registration

Exclusion Criteria:

* 1. Those subjects who are determined clinically unstable of the participation of this study as determined by the PI or treating physician will be excluded and asked to focus on their treatment.

Primary outcomes:
measure: Gut microbiomes in advanced/metastatic NSCLC patients
timeFrame: Up to 2 years
Secondary outcomes:
measure: Change in microbiome diversity and composition from baseline (prior to start of therapy) to first post-treatment evaluation scan.
timeFrame: Up to 2 years
measure: Clinical Response Rate (RR)
timeFrame: Up to 2 years
measure: Progression-Free Survival (PFS)
timeFrame: Up to 2 years
measure: Overall survival (OS)
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Orange
country: United States
facility: Chao Family Comprehensive Cancer Center University of California, Irvine
state: California
Study officials:
affiliation: Chao Family Comprehensive Cancer Center
name: Misako Nagasaka, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01623700: Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
Official title: A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Myocardial Infarction
Keywords: clopidogrel
aspirin
percutaneous coronary intervention
coronary stenting
antiplatelet
Lead sponsor: Uppsala University
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2012-06-20
Enrollment: 78000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients previously enrolled into the SWEDEHEART (RIKS-HIA/SCAAR/SEPHIA) registry from 1 Jan 2006 to 1 July 2010 with an event of ACS and observed during the index hospitalization following enrollment.

Brief summary: This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).

The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.


Eligibility criteria: Inclusion Criteria:

* Patient with an event of ACS under the study period
* Patient found in the National Registry of Drug Prescriptions and treated or not treated with antithrombotic drug/s (acetylsalicylic acid and/or either clopidogrel/ticlopidine/prasugrel and/or warfarin)

Exclusion Criteria:

* Patients will not be excluded from the database if they fulfill inclusion criteria.

Primary outcomes:
measure: number of patients with adverse events in patient groups with different antithrombotic treatment strategies
timeFrame: up to 5 years and 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University
state: Uppsala County
Study officials:
affiliation: Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology
name: Stefan James, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Varenhorst C, Jensevik K, Jernberg T, Sundstrom A, Hasvold P, Held C, Lagerqvist B, James S. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. Eur Heart J. 2014 Apr;35(15):969-78. doi: 10.1093/eurheartj/eht438. Epub 2013 Oct 11.
Clinical trial NCT02509000: Beijing Indoor Air Purifier Intervention Study
Official title: Beijing Indoor Air Purifier Intervention Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulmonary Disease
Lead sponsor: Peking University
Sponsor class: OTHER
Collaborators: name: Peking University Third Hospital
name: Utrecht University
First posted: 2015-07-27
Enrollment: 35
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study aimed to assess the impact of air filtration on indoor air quality and cardio-pulmonary health in residents living in high outdoor pollution settings in Beijing.


Eligibility criteria: Inclusion Criteria:

* Global Initiative for Chronic Obstructive Lung Disease criteria (mild to moderate, GOLD stage I\~II;
* severe to very severe, GOLD stage III\~IV) quit smoking for at least 1 year;
* a ratio of pre-bronchodilator forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) equal to or less than 0.70 and an increase of FEV1 with the use of 400μg of albuterol of less than 12% of the pre-bronchodilator one;
* no history of asthma or any other active lung disease.
* Subjects were free from exacerbations for at least 6 weeks.

Exclusion Criteria:

* Patients with heart pacemaker,
* heart failure with bundle-branch block,
* recent myocardial infarction (in the last 12 weeks) and
* anticoagulant therapy

Primary outcomes:
measure: respiratory inflammation
timeFrame: 4 weeks
Secondary outcomes:
measure: systemic inflammation
timeFrame: 4 weeks
measure: oxidative stress
timeFrame: 4 weeks
Other outcomes:
measure: lung function
timeFrame: 4 weeks
measure: autonomic function
timeFrame: 4 weeks
Locations:
Study officials:
affiliation: Peking University School of Public Health
name: Wei Huang, PhD
role: PRINCIPAL_INVESTIGATOR
References: